Moderna shares surge after it says experimental mRNA cancer treatment passed key test
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.pbs.org — the content belongs to PBS NewsHour.